Compound profiling is critical during the preclinical evaluation of drug candidates. Issues with metabolism and pharmacodynamics are the primary reasons for compound failure in clinical trials.
Fundacion MEDINA addresses preclinical issues by identifying potential liabilities of new leads in the early stages of the drug-discovery process:
MEDINA's facilities and services are state-of-the-art, and fast turn-around times are guaranteed by the screening platform’s high degree of automation.
MEDINA provides an advantage with its extensive experience garnered by its scientists at the MSD, Spain facilities, formerly the MRL Reference Center for drug safety.
MEDINA and Neuron BPh have reached an agreement to jointly publicize their technologies and pre-clinical integrated platform for the pharmaceutical industry.